Dantrolene for NMS: Not Recommended as Routine Treatment
Dantrolene is NOT indicated for neuroleptic malignant syndrome (NMS) and should not be used routinely, as the most recent high-quality evidence shows it is associated with increased mortality and prolonged hospitalization. 1, 2
Critical Evidence Against Routine Use
The FDA drug label explicitly states that dantrolene is not indicated for NMS treatment and warns that "patients may expire despite treatment with Dantrolene" 1. More importantly, the largest and most recent study (2026) examining 2,234 ICU-admitted NMS patients found that early dantrolene administration was associated with:
- Doubled in-hospital mortality (adjusted OR: 2.03,95% CI: 1.16-3.54) 2
- Prolonged ICU stay by approximately 2 days 2
- Prolonged hospital stay by approximately 7 days 2
These findings remained consistent across both propensity score matching and generalized linear mixed model analyses, and held true regardless of patient age 2.
Why the Confusion Exists
Important caveat: All the guideline evidence provided [3-4] addresses malignant hyperthermia (MH), not NMS—these are distinct conditions despite sharing some clinical features. Dantrolene is definitively the treatment of choice for MH 3, 4, but this does not translate to NMS efficacy.
The historical off-label use of dantrolene for NMS stems from:
- Mechanistic similarities between MH and NMS (both involve dysregulated calcium release)
- Older case reports showing apparent benefit 5, 6, 7
- Lack of large-scale controlled studies until recently
Evidence Quality Assessment
A 2007 systematic review of 271 NMS cases found that dantrolene monotherapy was associated with higher overall mortality and that combination treatments including dantrolene prolonged clinical recovery 8. The only potential benefit identified was shorter recovery time when NMS was caused by neuroleptic monotherapy specifically 8.
Recommended Approach to NMS Treatment
First-line management consists of:
Immediate discontinuation of the offending neuroleptic agent 1, 6
Aggressive supportive care:
- Cardiorespiratory stabilization
- Active cooling measures for hyperthermia
- Fluid resuscitation
- Monitoring for rhabdomyolysis and renal failure
- Electrolyte management
Consider bromocriptine or amantadine as specific pharmacologic agents if supportive care alone is insufficient 6
When Dantrolene Might Be Considered
Based on the limited evidence, dantrolene could potentially be considered only in:
- Severe, refractory cases not responding to supportive care and dopamine agonists
- Cases where NMS was triggered by neuroleptic monotherapy 8
- After careful risk-benefit discussion acknowledging the mortality data
If used, monitor closely for: muscle weakness, respiratory depression, hepatotoxicity, and thrombophlebitis 1.
Common Pitfall
Do not confuse malignant hyperthermia treatment protocols with NMS management. Despite superficial similarities, the evidence base for dantrolene differs dramatically between these conditions.